Adipotide
March 28, 2023Promising
5/10
Purrptide digest
Adipotide takes a genuinely aggressive approach to weight loss: it targets and destroys the blood vessels specifically feeding white fat tissue, starving fat cells of nutrients. Obese monkeys lost around 11% of their body weight in a four-week trial — fast and dramatic results, unlike the slower mechanisms of GLP-1 drugs. The approach also raised real safety concerns about kidney effects, since the targeting mechanism isn't perfectly fat-tissue-specific. Human trials have been notably cautious as a result.
What this means for you
🏃
If you care about weight/health
An aggressive mechanism with real safety questions attached — not something to pursue outside a properly monitored clinical trial.
🩺
If you're a clinician
The vascular-targeting mechanism carries genuine kidney safety concerns that have meaningfully slowed its clinical development path.
🔬
If you're a researcher
Targeting fat-tissue vasculature rather than appetite or metabolism is a mechanistically distinct approach worth comparing against GLP-1 strategies.
💸
If you follow biotech
Dramatic primate results but a bumpy safety profile have kept this from advancing as fast as the GLP-1 category.
BA
Barnhart et al.
MD Anderson Cancer Center
For the nerds
Adipose-targeted peptide reduces obesity in primates
Science Translational Medicine · DOI: 10.1126/scitranslmed.3002621
Read full paper on PubMed →